Atlas Trials

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer

Clinical trial NCT03847818 · UNKNOWN

Trial details

NCT number
NCT03847818
Sponsor
Shandong University
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
HER2-positive Breast Cancer
Start date
2019-03-01
Primary completion
2020-03-01
Enrollment
268

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.